



# Study Fact Sheet for Health Care Professionals

- 
- Trial Specifics**
- Phase III multicenter, randomized, double-blind, placebo-controlled, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's disease (AD)
  - Enrolling patients who are apolipoprotein E4 **non-carriers**

---

**Study Drug** Bapineuzumab is a monoclonal antibody developed to stimulate an immune reaction against the beta-amyloid protein with the objective of reducing or halting the progression of AD pathology

---

**Primary Trial Objective** To demonstrate an advantage of the efficacy of multiple doses of intravenously (IV) administered bapineuzumab in patients with mild to moderate AD over placebo

---

**Target Population** Males or females with mild to moderate Alzheimer's disease

- 
- Trial Design**
- Participants will be randomized to receive bapineuzumab or a placebo administered by IV infusion over approximately 60 minutes
  - 15 study visits over 83 weeks
  - IV infusion every 13 weeks; 6 doses total
  - The duration of each patient's participation is approximately 83 weeks

- 
- Key Inclusion Criteria**
- Males and females aged 50 to 88 years
  - Diagnosis of probable Alzheimer's disease
  - Mini-Mental State Examination (MMSE) score of 16–26, inclusive
  - Caregiver able to attend all study visits with participant

- 
- Key Exclusion Criteria**
- Significant neurological disease other than AD
  - Major psychiatric disorder
  - Significant systemic illness
  - History of stroke, seizure, or autoimmune disease
  - History of myocardial infarction within the last 2 years
- 

Approximately 2,050 patients will be randomized at 150–200 study sites in the U.S. and Canada.

For more information, visit [www.ICARASTUDY.COM](http://www.ICARASTUDY.COM)